Retrospective analysis of the efficacy of omalizumab in chronic refractory urticaria

Allergy and Asthma Proceedings

Volumn 35, Issue 5, 2013, Pages 446-452

  Viswanathan, Ravi K ^a   Moss, Mark H ^a   Mathur, Sameer K ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; CYCLOSPORIN A; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN E; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMALIZUMAB; STEROID; TACROLIMUS; THYROGLOBULIN ANTIBODY; THYROID PEROXIDASE ANTIBODY; ANTIIDIOTYPIC ANTIBODY; HISTAMINE H1 RECEPTOR ANTAGONIST; MONOCLONAL ANTIBODY;

ADULT; AGED; AUTOIMMUNITY; CHILD; CHRONIC URTICARIA; CLINICAL ARTICLE; CONFERENCE PAPER; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; MALE; MEDICAL RECORD REVIEW; PHENOTYPE; SCHOOL CHILD; STEROID THERAPY; TREATMENT DURATION; TREATMENT RESPONSE; ADOLESCENT; AUTOIMMUNE DISEASES; CHRONIC DISEASE; COMPLICATION; IMMUNOLOGY; MIDDLE AGED; RECURRENT DISEASE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; URTICARIA; YOUNG ADULT; ARTICLE; AUTOIMMUNE DISEASE;

ADOLESCENT; ADULT; AGED; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; AUTOIMMUNE DISEASES; CHILD; CHRONIC DISEASE; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; IMMUNOGLOBULIN E; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; URTICARIA; YOUNG ADULT;

EID: 84883687755     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2013.34.3694     Document Type: Conference Paper

References (31)

1. O'Donnell BF, Lawlor F, Simpson J, et al. The impact of chronic urticaria on the quality of life. Br J Dermatol 136:197-201, 1997.
2. Poon E, Seed PT, Greaves MW, and Kobza-Black A. The extent and nature of disability in different urticarial conditions. Br J Dermatol 140:667-671, 1999.
3. Hide M, Francis DM, Grattan CE, et al. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med 328:1599-1604, 1993.
4. Ferrer M, KinétJP, and Kaplan AP. Comparative studies of functional and binding assays for IgG anti-Fc(epsilon)RI(alpha) (alpha-subunit) in chronic urticaria. J Allergy Clin Immunol 101:672-676, 1998.
5. Biagtan MJ, Viswanathan RK, Evans MD, and Mathur SK. Clinical utility of the Chronic Urticaria Index. J Allergy Clin Immunol 127:1626-1627, 2011.
6. Viswanathan RK, Biagtan MJ, and Mathur SK. The role of autoimmune testing in chronic idiopathic urticaria. Ann Allergy Asthma Immunol 108:337-341.e1, 2012.
7. Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA2LEN/EDF/WAO guideline: Management of urticaria. Allergy 64:1427-1443, 2009.
8. Leung DY, Sampson HA, Yunginger JW, et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 348:986-993, 2003.
9. Foroughi S, Foster B, Kim N, et al. Anti-IgE treatment of eosinophil-associated gastrointestinal disorders. J Allergy Clin Immunol 120:594-601, 2007.
10. Molderings GJ, Raithel M, Kratz F, et al. Omalizumab treatment of systemic mast cell activation disease: Experiences from four cases. Intern Med 50:611-615, 2011. (PubMed PMID: 21422688.)
11. Pitt TJ, Cisneros N, Kalicinsky C, and Becker AB. Successful treatment of idiopathic anaphylaxis in an adolescent. J Allergy Clin Immunol 126:415-416, 2010.
12. Belloni B, Ziai M, Lim A, et al. Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol 120:1223-1225, 2007.
13. Park SY, Choi MR, Na JI, et al. Recalcitrant atopic dermatitis treated with omalizumab. Ann Dermatol 22:349-352, 2010.
14. Kim DH, Park KY, Kim BJ, et al. Anti-immunoglobulin E in the treatment of refractory atopic dermatitis. Clin Exp Dermatol 38:496-500, 2013.
15. Maurer M, Rosen K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 368:924-935, 2013.
16. Kaplan AP, Joseph K, Maykut RJ, et al. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol 122:569-573, 2008.
17. Magerl M, Staubach P, Altrichter S, et al. Effective treatment of therapy-resistant chronic spontaneous urticaria with omalizumab. J Allergy Clin Immunol 126:665-666, 2010.
18. Saini S, Rosen KE, Hsieh HJ, et al. A randomized, placebocontrolled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol 128:567-573.e1, 2011.
19. Buyukozturk S, Gelincik A, Demirturk M, et al. Omalizumab markedly improves urticaria activity scores and quality of life scores in chronic spontaneous urticaria patients: A real life survey. J Dermatol 39:439-442, 2012.
20. Nam YH, Kim JH, Jin HJ, et al. Effects of omalizumab treatment in patients with refractory chronic urticaria. Allergy Asthma Immunol Res 4:357-361, 2012.
21. Magen E, Mishal J, Zeldin Y, and Schlesinger M. Clinical and laboratory features of antihistamine-resistant chronic idiopathic urticaria. Allergy Asthma Proc 32:460-466, 2011.
22. Ferrer M, Gamboa P, Sanz ML, et al. Omalizumab is effective in nonautoimmune urticaria. J Allergy Clin Immunol 127:1300-1302, 2011.
23. Maurer M, Altrichter S, Bieber T, et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol 128:202-209e5, 2011.
24. Mlynek A, Zalewska-Janowska A, Martus P, et al. How to assess disease activity in patients with chronic urticaria? Allergy 63:777-780, 2008.
25. Eckman JA, Sterba PM, Kelly D, et al. Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge. J Allergy Clin Immunol 125:889-895.e7, 2010.
26. Beck LA, Marcotte GV, MacGlashan D, et al. Omalizumabinduced reductions in mast cell Fce psilon RI expression and function. J Allergy Clin Immunol 114:527-530, 2004.
27. Metz M, and Maurer M. Omalizumab in chronic urticaria. Curr Opin Allergy Clin Immunol 12:406-411, 2012.
28. Sanchez J, Ramirez R, Diez S, et al. Omalizumab beyond asthma. Allergol Immunopathol (Madr) 40):306-315, 2012.
29. Chipps BE, Figliomeni M, and Spector S. Omalizumab: An update on efficacy and safety in moderate-to-severe allergic asthma. Allergy Asthma Proc 33:377-385, 2012.
30. Corren J, Casale TB, Lanier B, et al. Safety and tolerability of omalizumab. Clin Exp Allergy 39:788-797, 2009.
31. Song CH, Stern S, Giruparajah M, et al. Long-term efficacy of fixed-dose omalizumab for patients with severe chronic spontaneous urticaria. Ann Allergy Asthma Immunol 110:113-117, 2013.